JP2022502501A - 新規使用 - Google Patents

新規使用 Download PDF

Info

Publication number
JP2022502501A
JP2022502501A JP2021540398A JP2021540398A JP2022502501A JP 2022502501 A JP2022502501 A JP 2022502501A JP 2021540398 A JP2021540398 A JP 2021540398A JP 2021540398 A JP2021540398 A JP 2021540398A JP 2022502501 A JP2022502501 A JP 2022502501A
Authority
JP
Japan
Prior art keywords
alkyl
virus
substituted
phenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021540398A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020069043A5 (https=
JP2022502501A5 (https=
Inventor
グレッチェン・スナイダー
ローレンス・ピー・ウェノグル
ジェニファー・オブライエン
ジョゼフ・ヘンドリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of JP2022502501A publication Critical patent/JP2022502501A/ja
Publication of JPWO2020069043A5 publication Critical patent/JPWO2020069043A5/ja
Publication of JP2022502501A5 publication Critical patent/JP2022502501A5/ja
Priority to JP2024082290A priority Critical patent/JP2024109735A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021540398A 2018-09-25 2019-09-25 新規使用 Pending JP2022502501A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024082290A JP2024109735A (ja) 2018-09-25 2024-05-21 新規使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736324P 2018-09-25 2018-09-25
US62/736,324 2018-09-25
PCT/US2019/053032 WO2020069043A1 (en) 2018-09-25 2019-09-25 Novel uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024082290A Division JP2024109735A (ja) 2018-09-25 2024-05-21 新規使用

Publications (3)

Publication Number Publication Date
JP2022502501A true JP2022502501A (ja) 2022-01-11
JPWO2020069043A5 JPWO2020069043A5 (https=) 2022-10-04
JP2022502501A5 JP2022502501A5 (https=) 2022-10-04

Family

ID=69953335

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021540398A Pending JP2022502501A (ja) 2018-09-25 2019-09-25 新規使用
JP2024082290A Pending JP2024109735A (ja) 2018-09-25 2024-05-21 新規使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024082290A Pending JP2024109735A (ja) 2018-09-25 2024-05-21 新規使用

Country Status (4)

Country Link
US (1) US20210338679A1 (https=)
EP (1) EP3856191A4 (https=)
JP (2) JP2022502501A (https=)
WO (1) WO2020069043A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12396992B2 (en) 2019-01-07 2025-08-26 Intra-Cellular Therapies, Inc. Organic compounds
AU2020343329C1 (en) 2019-09-03 2026-02-12 Intra-Cellular Therapies, Inc. Methods of treatment
WO2021127517A1 (en) * 2019-12-18 2021-06-24 Intra-Cellular Therapies, Inc. Novel uses
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease
WO2025212780A1 (en) * 2024-04-02 2025-10-09 Intra-Cellular Therapies, Inc. Organic compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049417A1 (en) * 2016-09-12 2018-03-15 Intra-Cellular Therapies, Inc. Novel uses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273750B2 (en) 2005-06-06 2012-09-25 Takeda Pharmaceutical Company Limited Organic compounds
JP5453086B2 (ja) 2006-06-06 2014-03-26 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
ES2588238T3 (es) 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
AU2008335811B2 (en) 2007-12-06 2012-05-17 Intra-Cellular Therapies, Inc. Organic compounds
JP5989993B2 (ja) 2008-12-06 2016-09-07 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2010065147A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
AU2009322904A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
KR20110098732A (ko) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN102231953A (zh) 2008-12-06 2011-11-02 细胞内治疗公司 有机化合物
EP2560676B8 (en) 2010-04-22 2016-10-12 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
US10695431B2 (en) * 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9308213B2 (en) * 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
WO2013138118A1 (en) * 2012-03-14 2013-09-19 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
CA2906640C (en) 2013-03-15 2021-07-20 Intra-Cellular Therapies, Inc. Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049417A1 (en) * 2016-09-12 2018-03-15 Intra-Cellular Therapies, Inc. Novel uses

Also Published As

Publication number Publication date
EP3856191A1 (en) 2021-08-04
EP3856191A4 (en) 2022-06-22
US20210338679A1 (en) 2021-11-04
JP2024109735A (ja) 2024-08-14
WO2020069043A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
JP2022502501A (ja) 新規使用
JP7030656B2 (ja) ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ－γキナーゼ阻害剤とを含有する薬学的組成物
JP7134168B6 (ja) 新規使用
JP6696904B2 (ja) 製剤および医薬組成物
KR20210073616A (ko) 면역-관련 및 염증성 질환의 치료
JP2006510634A (ja) １−（３，４−ジメトキシフェニル）−４−メチル−５−エチル−７−メトキシ−８−ヒドロキシ−５ｈ−２，３−ベンゾジアゼピンの製薬組成物及びその用途
Billah et al. Pharmacology of N-(3, 5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor
JP2019534304A (ja) 炎症性疾患の治療のための化合物及びその医薬組成物
JP2021536459A (ja) ベンズヒドリルチオアセトアミド化合物を有効成分として含む線維化疾患の治療用組成物
JP2022503785A (ja) チグリタザール及びその関連化合物の応用
US20060008421A1 (en) Pharmaceutical combination
US20220409566A1 (en) CCL5 Inhibitors
JPWO2003031414A1 (ja) 新規なヘテロ環化合物および抗炎症薬
JP2022505471A (ja) 新規使用
KR20230143611A (ko) 바이사이클릭 고리를 포함하는 tyk2 억제제 화합물
KR100685557B1 (ko) 아데노신 에이-2에이 수용체 작용제와 베타-2-아드레날린수용체 작용제의 약제 조합물
WO2017131097A1 (ja) アダマンタン誘導体およびその使用
US20030109485A1 (en) Pharmaceutical combination
JP2005522490A (ja) Ｐｔｘ３遺伝子発現抑制方法
JP7290223B2 (ja) ＩＬ－１β阻害薬
US11628171B2 (en) Method for treating brain or nerve injury
JPH04210667A (ja) 免疫抑制剤としてのフェニルアセトニトリルアルキルアミノアルキルーオルトー置換アリール化合物
US20230355625A1 (en) Methods of treatment
CN120225201A (zh) 治疗炎症性病状的方法
WO2026058000A2 (en) Methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240521

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240610

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240906